Glutathione Supplementation Shows Promise for Improving Insulin Sensitivity and Reducing Oxidative Damage in Type 2 Diabetes

In Type 2 Diabetes Mellitus (T2DM), glutathione (GSH) deficiency is a consistent hallmark, significantly contributing to oxidative stress, mitochondrial dysfunction, and chronic inflammation. These factors drive progressive organ damage and exacerbate disease progression. Current standard-of-care therapies often do not fully address the underlying oxidative burden. Given GSH's central role as the most abundant intracellular antioxidant, regulating redox homeostasis and cellular integrity, its augmentation presents a compelling strategy to mitigate these critical pathological processes in T2DM.

This review critically examined existing literature on Glutathione (GSH) supplementation and precursor strategies in Type 2 Diabetes (T2DM) and its complications. Researchers synthesized evidence from mechanistic studies, clinical trials, and translational research to assess efficacy in improving T2DM outcomes and evaluate overall safety profiles. The methodology involved a comprehensive analysis of published data to identify consistent findings, significant research gaps, and future directions for GSH-centered interventions, focusing on its role in redox homeostasis and cellular protection.

The review found that Glutathione (GSH) augmentation in T2DM is linked to improved insulin sensitivity, reduced oxidative damage, and better microvascular outcomes. While these findings are currently preliminary and heterogeneous, the overall safety profile of GSH and its precursors across populations is highly favorable.

Gastrointestinal discomfort was the most commonly reported adverse effect, with serious toxicities being rare. Both acute and chronic studies consistently reinforced the compatibility of GSH and its precursors with standard antiretroviral and antidiabetic therapies, suggesting a low risk of drug-drug interactions. The evidence collectively supports GSH-centered strategies as promising adjuncts for oxidative stress-driven chronic diseases, particularly in the context of T2DM where GSH deficiency is a consistent hallmark contributing to mitochondrial dysfunction and inflammation.